Contact - Uppsala University, Sweden

SNP&SEQ

Job opportunity
Although we are currently not advertising for any open job positions at the SNP&SEQ Technology Platform you are welcome to send a spontaneous application (CV + personal letter) to:
ann-christine.syvanen@medsci.uu.se.
We are constantly looking for experienced and skilled research engineers and bioinformaticians.

Director of the SNP&SEQ Technology Platform
and Research group leader:
Prof. Ann-Christine Syvänen
Email: Ann-Christine.Syvanen@medsci.uu.se
Phone: +46 (0) 18 611 29 59
Mobile: +46 (0) 70 167 94 45

SNP-Genotyping inquiries:
Tomas Axelsson, Manager - SNP-genotyping
Email: Tomas.Axelsson@medsci.uu.se
Phone: +46 (0) 18 611 26 44
Mobile: +46 (0) 70 167 94 58

Sequencing inquiries:
Ulrika Liljedahl, Manager - Illiumina sequencing
Email: seq@medsci.uu.se
Phone: +46 (0) 18 611 49 34
Mobile: +46 (0) 70 167 94 42

Address:   The SNP&SEQ Technology Platform
                Uppsala University Hospital
                Entr. 70, 3rd floor, Res. Dept. 2, lab. 20
                751 85 Uppsala
                Sweden

The SNP&SEQ Technology Platform at Uppsala University, Uppsala Sweden is located in the Research Department 2 & 3 at the Uppsala University Hospital, Entrance 70, 3rd floor.

(Click image to enlarge)

Find on

News
New equipment 2013-01-07 During Christmas the SNP&SEQ-platform installed a new HiSeq 2500-instrument. This instrument allows sequencing of 2 x 150 bp and decreases the run time from 11 days to 27 hours. Currently the SNP&SEQ-platform offers sequencing using four HiSeq- and one MiSeq-instrument.
Publication i Nature Genetics 2012-12-02 15 new loci for coronary artery disease were published on-line in Nature Genetics on December 2nd. Both the molecular medicine group and the SNP&SEQ platform were involved in the study.
Publication in Nature Genetics 2012-11-11 A new publication in Nature Genetics (Nov 11) presents identification of 14 new risk loci for rheumatoid arthritis (RA) by genotyping a custom designed Immunochip. For this study the SNP&SEQ-platform genotyped about 1000 samples from Umeå. There are now 46 known genetic risk loci for RA.
New equipment 2012-08-30 The SNP&SEQ Technology Platform has recently installed a third HiSeq2000 instrument and a second iScan instrument, including a new dual autoloader from Illumina.
Two publications in Nature Genetics 2012-08-12 Nature Genetics has published two large-scale association studies where the SNP&SEQ-platform have been involved by genotyping sub-sets of the samples.
Post doc grant 2012-06-06 Former group member Johanna Sandling has recieved an international post doc grant from VR-MH.
MolMed receives new grant 2012-04-23 Large grant for epigenetic and genomic analyses of the brain from VR, FAS, Formas and Vinnova to Molecular Medicine and the SNP&SEQ platform.
New sequencer, MiSeq 2012-03-16 The SNP&SEQ Technology Platform has installed a MiSeq instrument from Illumina.
The Swedish Childhood Cancer Foundation 2011-12-14 Molecular Medicine research group has received funding from the Swedish Childhood Cancer Foundation.
VR grant 2011-11-17 VR-RFI has granted 6.7 million SEK for running costs to the SNP&SEQ platform.
K&A Wallenberg grant 2011-10-04 Molecular Medicine research group has received funding from the K&A Wallenberg foundation.
European Project: ESGI 2011-01-18 The Molecular Medicine group contributes to the ESGI infra-structure by technology development, eg. allele-specific gene expression and epigenetics.

News

New equipment

2013-01-07

During Christmas the SNP&SEQ-platform installed a new HiSeq 2500-instrument. This instrument allows sequencing of 2 x 150 bp and decreases the run time from 11 days to 27 hours. Currently the SNP&SEQ-platform offers sequencing using four HiSeq- and one MiSeq-instrument.

Publication i Nature Genetics

2012-12-02

15 new loci for coronary artery disease were published on-line in Nature Genetics on December 2nd. Both the molecular medicine group and the SNP&SEQ platform were involved in the study.

Publication in Nature Genetics

2012-11-11

A new publication in Nature Genetics (Nov 11) presents identification of 14 new risk loci for rheumatoid arthritis (RA) by genotyping a custom designed Immunochip. For this study the SNP&SEQ-platform genotyped about 1000 samples from Umeå. There are now 46 known genetic risk loci for RA.

New equipment

2012-08-30

The SNP&SEQ Technology Platform has recently installed a third HiSeq2000 instrument and a second iScan instrument, including a new dual autoloader from Illumina.

Two publications in Nature Genetics

2012-08-12

Nature Genetics has published two large-scale association studies where the SNP&SEQ-platform have been involved by genotyping sub-sets of the samples.

Post doc grant

2012-06-06

Former group member Johanna Sandling has recieved an international post doc grant from VR-MH.

MolMed receives new grant

2012-04-23

Large grant for epigenetic and genomic analyses of the brain from VR, FAS, Formas and Vinnova to Molecular Medicine and the SNP&SEQ platform.

New sequencer, MiSeq

2012-03-16

The SNP&SEQ Technology Platform has installed a MiSeq instrument from Illumina.

The Swedish Childhood Cancer Foundation

2011-12-14

Molecular Medicine research group has received funding from the Swedish Childhood Cancer Foundation.

VR grant

2011-11-17

VR-RFI has granted 6.7 million SEK for running costs to the SNP&SEQ platform.

K&A Wallenberg grant

2011-10-04

Molecular Medicine research group has received funding from the K&A Wallenberg foundation.

European Project: ESGI

2011-01-18

The Molecular Medicine group contributes to the ESGI infra-structure by technology development, eg. allele-specific gene expression and epigenetics.